ArticleIn vivo (Athens, Greece)

Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery.

Nobuki Furubayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.